References
- Moore AR , RosenbergSC , McCormickF , MalekS. RAS-targeted therapies: is the undruggable drugged?Nat. Rev. Drug Discov.19(8), 533–552 (2020).
- Prior IA , HoodFE , HartleyJL. The frequency of RAS mutations in cancer. Cancer Res.80(14), 2969–2974 (2020).
- Simanshu DK , NissleyDV , McCormickF. RAS proteins and their regulators in human disease. Cell170(1), 17–33 (2017).
- Ni D , LiX , HeX , ZhangH , ZhangJ , LuS. Drugging K-RasG12C through covalent inhibitors: mission possible?Pharmacol. Ther.202, 1–17 (2019).
- Uprety D , AdjeiAA. KRAS: from undruggable to a druggable cancer target. Cancer Treat. Rev.89, 102070 (2020).
- Aran V , OmerovicJ. Current approaches in NSCLC targeting K-RAS and EGFR. Int. J. Mol. Sci.20(22), 5701 (2019).
- Karasic TB , ChioreanEG , SebtiSM , O’DwyerPJ. A Phase I study of GGTI-2418 (geranylgeranyl transferase I inhibitor) in patients with advanced solid tumors. Target. Oncol.14(5), 613–618 (2019).
- Montalvo SK , LiL , WestoverKD. Rationale for RAS mutation-tailored therapies. Future Oncol.13(3), 263–271 (2017).
- Gehringer M , LauferSA. Emerging and re-emerging warheads for targeted covalent inhibitors: applications in medicinal chemistry and chemical biology. J. Med. Chem.62(12), 5673–5724 (2019).
- Ostrem JM , PetersU , SosMLet al. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature503(7477), 548–551 (2013).
- Patricelli MP , JanesMR , LiLSet al. Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state. Cancer Discov.6(3), 316–329 (2016).
- Lito P , SolomonM , LiLSet al. Allele-specific inhibitors inactivate mutant KRASG12C by a trapping mechanism. Science351(6273), 604–608 (2016).
- Hong DS , FakihMG , StricklerJHet al. KRASG12C inhibition with sotorasib in advanced solid tumors. N. Engl. J. Med.383(13), 1207–1217 (2020).
- Hong DS . Durability of clinical benefit and biomarkers in patients (pts) with advanced non-small-cell lung cancer (NSCLC) treated with AMG 510 (sotorasib). Presented at: European Society for Medical Oncology Virtual Congress 2020.Virtual Congress (2020).
- Amgen . FDA approves Lumakras™ (sotorasib), the first and only targeted treatment for patients with KRASG12C-mutated locally advanced or metastatic non-small-cell lung cancer (2021). www.amgen.com/newsroom/press-releases/2021/05/fda-approves-lumakras-sotorasib-the-first-and-only-targeted-treatment-for-patients-with-kras-g12cmutated-locally-advanced-or-metastatic-nonsmall-cell-lung-cancer
- Riely G . KRYSTAL-1: activity and preliminary pharmacodynamic (PD) analysis of adagrasib (MRTX849) in patients (Pts) with advanced non-small-cell lung cancer (NSCLC) harboring KRASG12C mutation. Presented at: European Lung Cancer Virtual Congress 2021.Virtual Congress (2021).
- Mirati therapeutics . Mirati therapeutics’ Adagrasib receives breakthrough therapy designation from U.S. Food and Drug administration for patients with advanced non-small-cell lung cancer harboring the KRASG12C mutation (2021). www.ir.mirati.com/press-releases/press-release-details/2021/Mirati-Therapeutics-Adagrasib-Receives-Breakthrough-Therapy-Designation-from-U.S.-Food-and-Drug-Administration-for-Patients-with-Advanced-Non-Small-Cell-Lung-Cancer-Harboring-the-KRAS-G12C-Mutation/default.aspx
- Hunter JC , ManandharA , CarrascoMAet al. Biochemical and structural analysis of common cancer-associated KRAS mutations. Mol. Cancer Res.13(9), 1325–1335 (2015).
- Hallin J , EngstromLD , HargisLet al. The KRASG12C inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients. Cancer Discov.10(1), 54–71 (2020).
- Canon J , RexK , SaikiAYet al. The clinical KRAS(G12C) inhibitor AMG 510 drives antitumour immunity. Nature575(7781), 217–223 (2019).